Alprostadil (Caverject/MUSE) and Hormonal Contraceptives: Full Interaction Guide

What Is the Interaction Between Alprostadil and Hormonal Contraceptives?

No pharmacokinetic interaction exists between alprostadil and hormonal contraceptives. Alprostadil is a synthetic prostaglandin E1 (PGE1) analogue that undergoes rapid, near-complete pulmonary first-pass metabolism by the enzyme 15-hydroxy prostaglandin dehydrogenase (15-PGDH), not by CYP3A4, CYP2C9, or P-glycoprotein. Hormonal contraceptives, which do modulate CYP3A4, therefore have no meaningful route through which to alter alprostadil clearance.

The clinically relevant concern is pharmacodynamic and involves partner exposure, not a metabolic pathway overlap.

How Alprostadil Is Absorbed and Cleared

After intracavernosal injection of alprostadil 5 to 40 mcg (Caverject), the drug acts locally on penile smooth muscle via EP2 and EP3 prostaglandin receptors, producing arterial dilation and erection. Systemic absorption is low. A 1994 pharmacokinetic study published in the Journal of Urology measured peripheral venous alprostadil concentrations after 20 mcg intracavernosal injection and found levels that were at or below the 2 pg/mL assay detection limit in most subjects within 60 minutes.

After intraurethral administration of alprostadil 125 to 1,000 mcg (MUSE), approximately 80% of the absorbed dose is metabolized on the first pass through the lungs. The FDA-approved MUSE labeling states that peripheral plasma levels remain <10 pg/mL following therapeutic doses, a level with no clinically documented systemic pharmacodynamic effect in the partner.

What Hormonal Contraceptives Do in the Body

Combined oral contraceptives (COCs) containing ethinyl estradiol plus a progestin (levonorgestrel, norgestimate, drospirenone, desogestrel, or norethindrone) are metabolized primarily by CYP3A4. They also inhibit CYP3A4 modestly and may induce uridine diphosphate glucuronosyltransferase (UGT) isoforms. Progestin-only pills (norethindrone 0.35 mg daily), etonogestrel implant (Nexplanon), levonorgestrel intrauterine systems (Mirena, Kyleena), and depot medroxyprogesterone acetate (DMPA, Depo-Provera) share some of these metabolic characteristics.

Because alprostadil does not use any of these enzymatic pathways, none of the CYP3A4 or UGT activity of hormonal contraceptives modifies alprostadil pharmacokinetics. The interaction rating in structured DDI databases (Drugs.com clinical pharmacology module, Lexicomp) is listed as "no known interaction" for this pair.

Partner Exposure: The Only Pharmacodynamic Signal Worth Discussing

This is the one area that generates real clinical questions. Small quantities of alprostadil can be transferred vaginally during intercourse after MUSE or Caverject use. The concern is whether that transferred prostaglandin could affect a female partner.

Evidence From the MUSE Phase III Trial

The key MUSE phase III trial (N=1,511 men with erectile dysfunction across multiple etiologies) included a partner safety sub-analysis. The published report in the New England Journal of Medicine (Padma-Nathan et al., 1997) noted vaginal burning or stinging in approximately 5.8% of female partners. This was attributed to local prostaglandin E1 effects on vaginal mucosal tissue, not systemic absorption.

No hormonal effect, menstrual disruption, or contraceptive failure attributable to partner exposure was reported in that trial. The female partners were not systematically assessed for hormonal contraceptive status, which limits definitive conclusions, but no signal of contraceptive interference emerged across 1,511 couples over the study period [1].

What the FDA Label Says About Condoms

The FDA-approved prescribing information for MUSE states: "If the patient's female sexual partner is pregnant, intercourse should be performed with the use of a condom barrier because of the potential for prostaglandin E1 to cause uterine contractions." This instruction specifically addresses pregnant partners, not partners using hormonal contraception.

For non-pregnant partners using hormonal contraception, the FDA label does not require condom use on the basis of any contraceptive interaction. A condom remains advisable for STI prevention per standard-of-care guidance regardless of this specific DDI question.

Does Alprostadil Affect Contraceptive Efficacy?

No published trial or case series documents alprostadil reducing the efficacy of any hormonal contraceptive. The contraceptive mechanisms of COCs (ovulation suppression via LH and FSH inhibition), progestin-only implants (cervical mucus thickening, ovulation suppression), and LNG-IUS (endometrial and cervical effects) are not prostaglandin-dependent in a way that would be antagonized by exogenous PGE1 at the concentrations reached via partner transfer.

Prostaglandins do modulate the endometrium and cervix physiologically. However, the quantities involved in vaginal transfer from MUSE or Caverject are orders of magnitude below the doses used in obstetric prostaglandin applications (e.g., dinoprostone 10 mg vaginal insert, which delivers sustained local concentrations to induce cervical ripening). That obstetric context is not comparable to the trace transfer occurring during sexual intercourse after therapeutic alprostadil use.

Pharmacokinetic Deep Dive: CYP, P-gp, and UGT Profiles

Understanding why this interaction is absent requires examining the metabolism of each drug in detail.

Alprostadil Metabolism Pathway

Alprostadil (PGE1) is metabolized by two sequential steps. First, 15-PGDH oxidizes the 15-hydroxyl group to produce 15-keto-PGE1. Second, delta-13-reductase reduces the 13,14-double bond to produce 13,14-dihydro-15-keto-PGE1. Both enzymes are cytosolic and concentrated in lung, kidney, and liver tissue. Neither enzyme is a CYP isoform, a UDP-glucuronosyltransferase, or a sulfotransferase. P-glycoprotein does not transport alprostadil.

The metabolites are excreted primarily in urine (88% within 24 hours) with a small fecal fraction. The half-life of the parent compound is approximately 5 to 10 minutes in the systemic circulation.

Hormonal Contraceptive Metabolism Pathway

Ethinyl estradiol is hydroxylated by CYP3A4 and CYP2C9, then sulfated and glucuronidated. Levonorgestrel, norethindrone, and desogestrel are reduced by 3-alpha-hydroxysteroid dehydrogenase and oxidized by CYP3A4. Drospirenone is metabolized by CYP3A4. Etonogestrel (the active metabolite of desogestrel) is also CYP3A4-dependent.

Since alprostadil does not use CYP3A4 and hormonal contraceptives do not use 15-PGDH, there is no shared metabolic pathway and no competitive inhibition or induction possible between the two drug classes.

P-glycoprotein Considerations

Neither alprostadil nor any approved hormonal contraceptive at standard doses produces clinically significant P-glycoprotein inhibition or induction. Ethinyl estradiol has been shown to modestly inhibit P-gp in vitro, but this effect has not been demonstrated to be clinically relevant even for known P-gp substrates at therapeutic EE doses of 20 to 35 mcg daily.

Hemodynamic Pharmacodynamics: Could There Be Additive Vasodilation?

Alprostadil produces local penile vasodilation via smooth muscle relaxation. At the systemic concentrations reached after intracavernosal or intraurethral dosing, measured blood pressure reductions are minimal. The Caverject FDA label reports that mean systemic blood pressure fell by 6 to 8 mmHg systolic after intracavernosal doses of 20 mcg in pharmacodynamic studies, returning to baseline within 2 hours.

Ethinyl estradiol-containing contraceptives can modestly increase blood pressure over time through renin-angiotensin-aldosterone system activation. This is a slow, cumulative hemodynamic effect, not acute vasodilation. Progestin-only methods have minimal hemodynamic effects at standard doses.

The combination does not create additive hypotension in either the patient using alprostadil or the partner exposed via sexual contact. No case reports of symptomatic hypotension attributable to this combination appear in the PubMed literature as of January 2025.

Clinical Decision Framework: Counseling the Alprostadil User With a Hormonal Contraceptive-Using Partner

The three questions a clinician should address during counseling are: (1) Is the partner pregnant or could she become pregnant? (2) Is either party concerned about STI risk? (3) Does the patient have a condition that makes even minimal systemic prostaglandin exposure a concern?

Question 1: Pregnancy Status of the Partner

If the partner is pregnant, the FDA label is explicit: use a condom to prevent intrauterine prostaglandin exposure that could stimulate uterine contractions. This recommendation applies regardless of whether the partner is simultaneously using a hormonal contraceptive (some women continue hormonal formulations unknowingly in early pregnancy before confirmation).

If the partner is not pregnant and is reliably using hormonal contraception, no condom is required specifically for the alprostadil-contraceptive interaction. The standard conversation about STI protection still applies.

Question 2: STI Risk

Alprostadil use does not eliminate the need for barrier contraception in situations where STI transmission is a concern. Condom use for STI prevention is a separate conversation from the DDI question but belongs in the same counseling visit.

Question 3: Systemic Prostaglandin Sensitivity in the Partner

Partners with known asthma, a history of vaginal prostaglandin sensitivity, or conditions sensitive to prostaglandin fluctuation (e.g., active inflammatory bowel disease involving prostaglandin-mediated inflammation) may experience local mucosal irritation. This is the same category of effect documented in 5.8% of MUSE trial partners (vaginal burning). Using a condom eliminates this risk.

Alprostadil Dose Forms and Their Relevance to Interaction Risk

Caverject Intracavernosal Injection (5 to 40 mcg)

Caverject Impulse is supplied as a dual-chamber syringe delivering alprostadil 10 or 20 mcg. The intracavernosal route produces the lowest systemic exposure of any alprostadil formulation. Local concentrations in corpus cavernosum tissue are high; peripheral venous concentrations rarely exceed baseline. The risk of pharmacodynamically relevant partner transfer from Caverject is lower than from MUSE.

MUSE Intraurethral Suppository (125 to 1,000 mcg)

MUSE delivers doses up to 25-fold higher than Caverject on a mcg basis. The urethral mucosa absorbs a fraction of each dose; some drug may appear in pre-ejaculatory or seminal fluid fractions. Transfer to vaginal tissue is plausible and was the basis of the partner safety data in Padma-Nathan et al. The 5.8% vaginal burning rate supports real, if minor, local PGE1 activity in partners. This route carries the highest theoretical interaction signal, even though no contraceptive failure has been documented.

Topical Alprostadil (Vitaros, Not FDA Approved in the US)

Topical alprostadil cream (Vitaros, approved in Canada and the EU at 300 mcg/dose) has a different absorption profile. Canadian labeling recommends avoiding vaginal contact with the cream itself. This formulation is not relevant to the US patient, but clinicians treating patients who source Vitaros internationally should note the additional warning.

Monitoring and Dose-Adjustment Recommendations

No dose adjustment of alprostadil is required based on concurrent hormonal contraceptive use, and no monitoring of contraceptive hormone levels is required based on alprostadil use. This applies to:

• Combined oral contraceptives (any progestin formulation)
• Progestin-only pills (norethindrone 0.35 mg)
• Etonogestrel subdermal implant (Nexplanon 68 mg, 3-year duration)
• Levonorgestrel intrauterine systems (Mirena 52 mg, Kyleena 19.5 mg, Liletta 52 mg)
• Depot medroxyprogesterone acetate (Depo-Provera 150 mg IM every 13 weeks)
• Combined hormonal patch (Xulane, 35 mcg EE/203 mcg norelgestromin weekly)
• Combined vaginal ring (NuvaRing, 15 mcg EE/120 mcg etonogestrel daily)

If a patient or partner reports new vaginal discomfort after MUSE use, condom use at subsequent encounters eliminates the exposure source without any need to modify either the alprostadil regimen or the contraceptive method.

What the AUA Erectile Dysfunction Guideline Says

The American Urological Association 2018 Erectile Dysfunction Guideline (amended 2024) states that intracavernosal alprostadil and intraurethral alprostadil are first-line therapies for men with ED who do not respond to or cannot use phosphodiesterase-5 inhibitors [2]. The guideline does not list hormonal contraceptives in the drug interaction section because no clinical interaction has been identified.

The AUA guideline does recommend patient education on proper administration, expected duration of effect (typically 30 to 60 minutes), and partner communication. It notes that prolonged erection lasting more than 4 hours (priapism) requires emergency evaluation; this risk is not modified by the partner's contraceptive status.

As the AUA guideline states directly: "Clinicians should inform patients about the importance of following the recommended dosage and administration technique to minimize adverse events and optimize efficacy" [2]. Partner drug interactions are not listed as a counseling priority for alprostadil.

Drug-Drug Interactions That Are Relevant for Alprostadil (For Complete Clinical Context)

While hormonal contraceptives do not interact with alprostadil, several drug classes do warrant caution in patients using alprostadil:

• Antihypertensives and vasodilators (including PDE5 inhibitors such as sildenafil, tadalafil, avanafil): additive hypotension is the main risk. Combining intracavernosal alprostadil with any PDE5 inhibitor is not recommended per FDA labeling due to risk of prolonged hypotension and priapism.
• Anticoagulants (warfarin, apixaban, rivaroxaban): intracavernosal injection carries a bleeding risk at the injection site; INR should be stable before initiating Caverject in patients on anticoagulation.
• Sympathomimetics (e.g., phenylephrine): used as an antidote for alprostadil-induced priapism, not an interaction to avoid but one to have available.
• Vasoactive agents for blood pressure management: alpha-blockers such as tamsulosin or doxazosin used for benign prostatic hyperplasia may add to systemic hypotensive effects.

None of these interactions involve hormonal contraceptives.

Patient Counseling Checklist

When a patient receiving alprostadil asks about their partner's use of hormonal contraceptives, address these points:

1. Reassure the patient that hormonal contraceptives will not reduce alprostadil's effectiveness and that alprostadil will not reduce the contraceptive's effectiveness.
2. If the partner is pregnant or pregnancy status is uncertain, use a condom per FDA labeling.
3. If the partner experiences vaginal burning or irritation after MUSE-assisted intercourse, using a condom at future encounters resolves the issue without stopping either medication.
4. Document the conversation in the chart, noting the patient was counseled on the absence of a pharmacokinetic interaction and the minor local exposure risk with MUSE.
5. Review STI risk separately and recommend condoms if indicated by the clinical picture.